Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

AstraZeneca PLC - American Depositary Shares (NQ: AZN )

75.52 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
64 65 Next >
AstraZeneca's Current Valuation Not Reflective Of Its Strong Fundamentals, Analyst Says
Via Benzinga
Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer
From Tempus
Via Business Wire
AstraZeneca Stock Scores Relative Strength Rating Upgrade
AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
What Does AstraZeneca's Debt Look Like?
Shares of AstraZeneca Inc. (NASDAQ:AZN) moved higher by 28.78% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its... 
Via Benzinga
3 Top Healthcare Stocks Defying the Bear Market
These healthcare companies look poised to continue their runs. 
Via The Motley Fool
Why Shares of Compugen Rose on Thursday
The clinical-stage biotech retreated a bit from one of its biggest days in a while. 
Via The Motley Fool
This Favorable Sign Appears On AstraZeneca's Chart
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study
Via Benzinga
Got $1,000? 5 Sensational Stocks to Buy to Start 2023 With a Bang
You don't need a mountain of money to grow your wealth on Wall Street. 
Via The Motley Fool
2 Market-Beating Stocks to Buy in 2023 and Hold Forever
For these companies' shareholders, it may be tempting to take profits right now. But both stocks can keep growing for a while. 
Via The Motley Fool
The Top Healthcare Stocks to Buy With $100
Healthcare is a sector that has proven to be reliable in recessions. 
Via The Motley Fool
Europe Approves AstraZeneca's Two Combo Therapies For Prostate, Bile Duct Cancer Settings
Via Benzinga
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
Via Benzinga
Could AstraZeneca's Asthma Drug Candidate Generate Billions?
AstraZeneca's new asthma rescue treatment could soon be approved in the United States for adults. 
Via The Motley Fool
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum 
Via MarketBeat
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
Via Benzinga
AstraZeneca Drug Imfinzi Fails As Monotherapy In Metastatic Lung Cancer Setting
Via Benzinga
Guardant Health (GH) Stock Sinks on Disappointing Blood Test Results
Guardant spent more money than it took in while hoping to become a leader in cancer diagnosis, but accuracy remains a problem. 
Via InvestorPlace
2 Best Biotech Stocks to Buy Right Now
Demand for medicines and vaccines has nowhere to go but up over the long run. 
Via The Motley Fool
FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza
Via Benzinga
AstraZeneca Awards $4M to Nonprofit Organizations to Advance Health Equity
From AstraZeneca
Via Business Wire
Mirati Wins FDA Approval For Amgen-Rivaling Cancer Drug As Wild Stock Swing Continues
FDA action on its KRAS-blocking drug could help recently downtrodden Mirati. 
Via Investor's Business Daily
2 Top Healthcare Stocks to Buy for the Long Haul
These two companies are just getting started. 
Via The Motley Fool
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
Via Benzinga
AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials
Via Benzinga
Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)
From AstraZeneca
Via Business Wire
Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer
From AstraZeneca
Via Business Wire
AstraZeneca's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
From AstraZeneca
Via Business Wire
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.